195 related articles for article (PubMed ID: 35864174)
1. TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.
Gu Y; Gao H; Zhang H; John A; Zhu X; Shivaram S; Yu J; Weinshilboum RM; Wang L
Oncogene; 2022 Aug; 41(35):4119-4129. PubMed ID: 35864174
[TBL] [Abstract][Full Text] [Related]
2. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis.
Zhang L; Zhou F; García de Vinuesa A; de Kruijf EM; Mesker WE; Hui L; Drabsch Y; Li Y; Bauer A; Rousseau A; Sheppard KA; Mickanin C; Kuppen PJ; Lu CX; Ten Dijke P
Mol Cell; 2013 Sep; 51(5):559-72. PubMed ID: 23973329
[TBL] [Abstract][Full Text] [Related]
3. TRAF4 positively regulates the osteogenic differentiation of mesenchymal stem cells by acting as an E3 ubiquitin ligase to degrade Smurf2.
Li J; Wang P; Xie Z; Wang S; Cen S; Li M; Liu W; Tang S; Ye G; Zheng G; Su H; Ma M; Wu X; Wu Y; Shen H
Cell Death Differ; 2019 Dec; 26(12):2652-2666. PubMed ID: 31076633
[TBL] [Abstract][Full Text] [Related]
4. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
Qiu N; He YF; Zhang SM; Zhan YT; Han GD; Jiang M; He WX; Zhou J; Liang HL; Ao X; Xia HM; Li J; Yang YY; He ZM; Zou ZZ; Li HS
Cancer Lett; 2019 Nov; 464():25-36. PubMed ID: 31461670
[TBL] [Abstract][Full Text] [Related]
5. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
6. IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.
White CD; Li Z; Dillon DA; Sacks DB
J Biol Chem; 2011 Aug; 286(34):29734-47. PubMed ID: 21724847
[TBL] [Abstract][Full Text] [Related]
7. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
9. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells.
Kim D; Nam GY; Seo E; Jun HS
J Biomed Sci; 2022 May; 29(1):31. PubMed ID: 35538534
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
Kwon YS; Nam KS; Kim S
Biochem Pharmacol; 2021 Aug; 190():114635. PubMed ID: 34058187
[TBL] [Abstract][Full Text] [Related]
12. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
13. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
Baldassarre T; Truesdell P; Craig AW
Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
[TBL] [Abstract][Full Text] [Related]
14. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
16. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
18. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
[TBL] [Abstract][Full Text] [Related]
19. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
Kim YJ; Sung D; Oh E; Cho Y; Cho TM; Farrand L; Seo JH; Kim JY
Cancer Lett; 2018 Jan; 412():118-130. PubMed ID: 29080749
[TBL] [Abstract][Full Text] [Related]
20. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
